This is a StreetInsider.com Premium Only Page

Gilead Sciences (GILD) –

Apr 25, 2024 04:56 PM Gilead Sciences (GILD) Misses Q1 EPS by 288c

Apr 25, 2024 04:11 PM Gilead posts quarterly loss on acquisition charge, revenue rises 5%

Apr 25, 2024 04:05 PM Form 8-K GILEAD SCIENCES, INC. For: Apr 25

Apr 25, 2024 04:02 PM Gilead Sciences Announces First Quarter 2024 Financial Results

Apr 24, 2024 01:32 PM HSBC Upgrades Gilead Sciences (GILD) to Hold

Apr 24, 2024 10:50 AM Gilead Sciences (GILD) April weekly option implied volatility into quarter results

Apr 17, 2024 08:14 AM Gilead Sciences (GILD) PT Lowered to $75 at UBS

Apr 15, 2024 04:48 PM Truist Securities Assumes Gilead Sciences (GILD) at Hold

Apr 9, 2024 09:40 AM Gilead Sciences (GILD) PT Lowered to $80 at Morgan Stanley

Apr 8, 2024 04:05 PM Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

Apr 2, 2024 06:39 PM Form 4 GILEAD SCIENCES, INC. For: Apr 01 Filed by: Parsey Merdad

Apr 2, 2024 07:06 AM Nurix Therapeutics (NRIX) Announces Extension of Collaboration with Gilead Sciences (GILD)

Apr 1, 2024 04:55 PM Form 144 GILEAD SCIENCES, INC. Filed by: Parsey Merdad

Mar 29, 2024 05:20 PM Form 4 GILEAD SCIENCES, INC. For: Mar 28 Filed by: Lofton Kevin E

Mar 28, 2024 04:24 PM Form ARS GILEAD SCIENCES, INC. For: Dec 31

Mar 28, 2024 04:14 PM Form DEF 14A GILEAD SCIENCES, INC. For: May 08

Mar 28, 2024 04:10 PM Form DEFA14A GILEAD SCIENCES, INC.

Mar 28, 2024 08:31 AM FDA Expands Indication for Gilead's (GILD) Vemlidy to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Mar 28, 2024 08:30 AM FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Mar 28, 2024 07:05 AM Xilio Therapeutics (XLO) Announces $11.3 Million Private Placement Equity Financing, License Agreement with Gilead (GILD)

Mar 28, 2024 07:02 AM Gilead Sciences (GILD) and Xilio (XLO) Enter Exclusive License Agreement for Tumor-Activated IL-12 Program

Mar 28, 2024 07:00 AM Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Mar 22, 2024 09:56 AM Gilead (GILD) reduces 2024 earnings guidance after completing CymaBay takeover

Mar 22, 2024 09:21 AM Form 8-K GILEAD SCIENCES, INC. For: Mar 22

Mar 22, 2024 09:18 AM Gilead Sciences (GILD) Announces Completion of Acquisition of CymaBay (CBAY)

Mar 22, 2024 09:18 AM Gilead Sciences Announces Completion of Acquisition of CymaBay

Mar 18, 2024 07:29 PM Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Mar 18, 2024 04:08 PM Form PRE 14A GILEAD SCIENCES, INC. For: May 08

Mar 15, 2024 10:25 AM BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)

Mar 14, 2024 04:09 PM Gilead Sciences (GILD) Board Member Kevin Lofton to Retire

Mar 14, 2024 04:06 PM Form 8-K GILEAD SCIENCES, INC. For: Mar 10

Mar 12, 2024 04:19 PM Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Telman Deborah H

Mar 12, 2024 03:58 PM Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Patterson Sandra

Mar 11, 2024 09:15 PM Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Parsey Merdad

Mar 11, 2024 09:12 PM Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: O'Day Daniel Patrick

Mar 11, 2024 09:03 PM Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Mercier Johanna

Mar 11, 2024 09:00 PM Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Dickinson Andrew D

Mar 11, 2024 08:24 AM Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay (CBAY) Tender Offer

Mar 11, 2024 08:24 AM Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Mar 8, 2024 01:21 PM Oppenheimer remain bullish on Gilead Sciences (GILD), HIV agents in 24/25 could provide conviction to investors

Mar 6, 2024 10:25 AM Gilead Sciences (GILD) and Merck (MRK) Report Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Mar 6, 2024 10:25 AM Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Mar 6, 2024 08:01 AM Gilead Sciences (GILD), Merus (MRUS) Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Mar 6, 2024 08:00 AM Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Mar 5, 2024 04:35 PM Gilead Sciences (GILD) Reports New Real-World Data Supporting the Use of Veklury for People Hospitalized With COVID-19

Mar 5, 2024 04:35 PM New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

Mar 5, 2024 04:31 PM Gilead Sciences (GILD) HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Mar 5, 2024 04:30 PM Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Mar 5, 2024 07:03 AM RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Mar 5, 2024 07:00 AM RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs